MedTrace Logo

An Extension Study for Patients Previously Treated With ARQ 501

NCT00622063 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2013-02-28

No results posted yet for this study

Summary

To provide ongoing treatment with ARQ 501 for patients who have benefited from prior treatment with ARQ 501

Conditions

Interventions

DRUG

ARQ 501

Treatment with ARQ 501 or ARQ 501 as combination therapy at the dose and regimen previously received

Sponsors & Collaborators

  • ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

    lead INDUSTRY

Principal Investigators

  • Neil Nathan Senzer, MD · Mary Crowley Medical Research Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2008-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00622063 on ClinicalTrials.gov